SELLAS (SLS) is poised for significant upside as critical Phase 3 data is imminent, potentially changing the standard of care for leukemia.
Source Post
SELLAS (SLS) Phase 3 Data Imminent – Buy Now for 100% Upside! | SLS Stock Analysis
Investing Talk PodcastMay 18, 2026
The podcast analyzes SELLAS Life Sciences (SLS), a clinical-stage biopharmaceutical company awaiting critical Phase 3 trial data for a leukemia treatment. The imminent unblinding of the Regal trial, which is nearing its final patient event count, is creating significant market volatility. The company currently has zero revenue, which is standard for its stage, but the upcoming data is expected to fundamentally change its valuation.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
SLS
buy opened May 18, 2026
+14.27%